Corium International Inc

Corium International — Corporate Update (February 2016)

10 slides from Corium International's corporate update, Feb 3, 2016

  1. Slide 1: Forward-looking Statements

    Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial timing and plans, the achieveme

  2. Slide 2: Phase 1 Study Overview

    Phase 1 Study Overview Open label, two-period crossover study Two sequential treatments: Donepezil TDS, single-dose, once-weekly patch targeted to deliver 5 mg /day Oral Aricept 5 mg as comparator, one 5 mg tablet administered once daily for 7 days 9 healthy volunteers (50-80 years of age) received

  3. Slide 3: 7-day Delivery Demonstrated

    7-day Delivery Demonstrated Oral Aricept: administered once daily for 7 days; plasma sampling during Day 1 and on Days 7 through 14 Donepezil TDS: single application of once-weekly TDS; plasma sampling during patch application (Days 1-7) and post patch removal (Days 8-15) Corplex Donepezil TDS achie

  4. Slide 4: Sustained and Controlled Delivery Demonstrated

    Sustained and Controlled Delivery Demonstrated Oral Aricept: administered once daily for 7 days; plasma sampling on Day 7 (0-24 hours) Donepezil TDS: single application of once-weekly patch with plasma sampling on Day 7 (0-24 hours) Sustained PK profile on Day 7 Controlled delivery with minimal peak

  5. Slide 5: Sustained and controlled TDS delivery at steady state

    Sustained and controlled TDS delivery at steady state* Corplex Donepezil plasma exposure at steady state similar to oral** Supports PK-based justification for product approval Comparable PK to Oral Projected at Steady State * TDS steady-state concentrations projected for Week 4 immediately after fou

  6. Slide 6: Potential Basis for Bioequivalence Approach

    Potential Basis for Bioequivalence Approach Geometric Mean Ratio TDS:Oral for PK parameters were between 90%-110% Intra-subject coefficient of variation was 36% Acceptance criteria for bioequivalence are 90% confidence intervals within 80%-125% limits 110 subjects in a two-way crossover study design

  7. Slide 7: Acceptable Safety and Skin Tolerability

    Acceptable Safety and Skin Tolerability Local skin tolerability No/mild skin irritation (erythema) Erythema transient and self-resolving Mild and self-resolving itching (pruritus) in some subjects Systemic safety Adverse events characteristic of Aricept and expected for the dosages used No adverse e

  8. Slide 8: Key Phase 1 Conclusions

    Key Phase 1 Conclusions Acceptable safety and skin tolerability Sustained and controlled PK in target age group (50-80) with once-weekly patch Achievement of plasma concentrations in excess of 5 mg oral Aricept Mean plasma concentrations at steady state projected to approximate 10 mg oral Similar ac

  9. Slide 9: Corium International, Inc.

    Nasdaq: CORI Corium International, Inc.

  10. Slide 10: Corium International, Inc.

    Corium International, Inc. Nasdaq: CORI €orium February 3, 2016

Corium International — Corporate Update (February 2016) on 6ix